12 results on '"Jeremic, Branislav"'
Search Results
2. Time-synchronized immune-guided SBRT partial bulky tumor irradiation targeting hypoxic segment while sparing the peritumoral immune microenvironment
- Author
-
Tubin, Slavisa, Ashdown, Martin, and Jeremic, Branislav
- Published
- 2019
- Full Text
- View/download PDF
3. Mono-institutional phase 2 study of innovative Stereotactic Body RadioTherapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) clonogenic cells in unresectable bulky non-small cell lung cancer: profound non-targeted effects by sparing peri-tumoral immune microenvironment
- Author
-
Tubin, Slavisa, Khan, Mohammad K., Salerno, Gerardo, Mourad, Waleed F., Yan, Weisi, and Jeremic, Branislav
- Published
- 2019
- Full Text
- View/download PDF
4. Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database
- Author
-
Cihoric, Nikola, Vlaskou Badra, Eugenia, Tsikkinis, Alexandros, Prasad, Vikas, Kroeze, Stephanie, Igrutinovic, Ivan, Jeremic, Branislav, Beck, Marcus, Zschaeck, Sebastian, Wust, Peter, and Ghadjar, Pirus
- Published
- 2018
- Full Text
- View/download PDF
5. Current status and perspectives of interventional clinical trials for glioblastoma - analysis of ClinicalTrials.gov.
- Author
-
Cihoric, Nikola, Tsikkinis, Alexandros, Minniti, Giuseppe, Lagerwaard, Frank J., Herrlinger, Ulrich, Mathier, Etienne, Soldatovic, Ivan, Jeremic, Branislav, Ghadjar, Pirus, Elicin, Olgun, Lössl, Kristina, Aebersold, Daniel M., Belka, Claus, Herrmann, Evelyn, and Niyazi, Maximilian
- Subjects
CLINICAL trials ,GLIOBLASTOMA multiforme ,CENTRAL nervous system cancer ,RADIOTHERAPY ,AUTOREGRESSIVE models ,GLIOMA treatment ,EXPERIMENTAL design - Abstract
The records of 208.777 (100%) clinical trials registered at ClinicalTrials.gov were downloaded on the 19th of February 2016. Phase II and III trials including patients with glioblastoma were selected for further classification and analysis. Based on the disease settings, trials were classified into three groups: newly diagnosed glioblastoma, recurrent disease and trials with no differentiation according to disease setting. Furthermore, we categorized trials according to the experimental interventions, the primary sponsor, the source of financial support and trial design elements. Trends were evaluated using the autoregressive integrated moving average model. Two hundred sixteen (0.1%) trials were selected for further analysis. Academic centers (investigator initiated trials) were recorded as primary sponsors in 56.9% of trials, followed by industry 25.9%. Industry was the leading source of monetary support for the selected trials in 44.4%, followed by 25% of trials with primarily academic financial support. The number of newly initiated trials between 2005 and 2015 shows a positive trend, mainly through an increase in phase II trials, whereas phase III trials show a negative trend. The vast majority of trials evaluate forms of different systemic treatments (91.2%). In total, one hundred different molecular entities or biologicals were identified. Of those, 60% were involving drugs specifically designed for central nervous system malignancies. Trials that specifically address radiotherapy, surgery, imaging and other therapeutic or diagnostic methods appear to be rare. Current research in glioblastoma is mainly driven or sponsored by industry, academic medical oncologists and neuro-oncologists, with the majority of trials evaluating forms of systemic therapies. Few trials reach phase III. Imaging, radiation therapy and surgical procedures are underrepresented in current trials portfolios. Optimization in research portfolio for glioblastoma is needed. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
6. Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database.
- Author
-
Cihoric, Nikola, Tsikkinis, Alexandros, Gutierrez Miguelez, Cristina, Strnad, Vratislav, Soldatovic, Ivan, Ghadjar, Pirus, Jeremic, Branislav, Dal Pra, Alan, Aebersold, Daniel M., Lössl, Kristina, and Miguelez, Cristina Gutierrez
- Subjects
RADIOISOTOPE brachytherapy ,RADIOTHERAPY ,CLINICAL trials ,PROSTATE cancer ,BREAST cancer ,DATABASES ,ESOPHAGEAL tumors ,HEAD tumors ,LONGITUDINAL method ,NECK tumors ,PROSTATE tumors ,RADIATION doses ,TUMORS ,CERVIX uteri tumors ,ENDOMETRIAL tumors - Abstract
Background: To evaluate the current status of prospective interventional clinical trials that includes brachytherapy (BT) procedures.Methods: The records of 175,538 (100 %) clinical trials registered at ClinicalTrials.gov were downloaded on September 2014 and a database was established. Trials using BT as an intervention were identified for further analyses. The selected trials were manually categorized according to indication(s), BT source, applied dose rate, primary sponsor type, location, protocol initiator and funding source. We analyzed trials across 8 available trial protocol elements registered within the database.Results: In total 245 clinical trials were identified, 147 with BT as primary investigated treatment modality and 98 that included BT as an optional treatment component or as part of the standard treatment. Academic centers were the most frequent protocol initiators in trials where BT was the primary investigational treatment modality (p < 0.01). High dose rate (HDR) BT was the most frequently investigated type of BT dose rate (46.3 %) followed by low dose rate (LDR) (42.0 %). Prostate was the most frequently investigated tumor entity in trials with BT as the primary treatment modality (40.1 %) followed by breast cancer (17.0 %). BT was rarely the primary investigated treatment modality for cervical cancer (6.8 %).Conclusion: Most clinical trials using BT are predominantly in early phases, investigator-initiated and with low accrual numbers. Current investigational activities that include BT mainly focus on prostate and breast cancers. Important questions concerning the optimal usage of BT will not be answered in the near future. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
7. Analysis of cervical resistance during continuous controllable balloon dilatation: controlled clinical and experimental study.
- Author
-
Arsenijevic, Petar, Milosevic, Marko, Zivanovic, Aleksandar, Milicic, Biljana, Jeremic, Branislav, Filipovic, Nenad, Protrka, Zoran, Todorovic, Petar, and Arsenijevic, Slobodan
- Subjects
PUPILLARY reflex ,MISCARRIAGE - Abstract
Background: Hydraulic dilatation is a novel method of cervical dilatation that is based on continuous controllable dilatation (CCBD) by the pumping of fluid into the balloon extension of the system. The main advantage of this procedure is that it allows control of and insight into the process of cervical dilatation. Methods: For the purposes of our research, we created a new and upgraded system for CCBD which consists of a programmed hydrostatic pump connected to a balloon extension. With regard to our aim to precisely measure and determine the location of the cervical resistance, we placed two pressure-measuring films, one on the top and one on the bottom of the balloon extension. This study included 42 patients in whom cervical resistance was measured before suction curettage. Results: Cervical dilatation and measurement of cervical resistance were successful in all patients. The analysis of the pressure-measuring films showed that the points of highest resistance were located in the zone of the internal cervical os and that these values were much higher than those in the zone of the external cervical os (0.402 versus 0.264 MPa at the upper pressure-sensitive film; 0.387 versus 0.243 MPa at the lower pressure-sensitive film). This study also showed that an increase in cervical resistance in the zone of the internal cervical os was followed by an increase in cervical resistance in the zone of the external cervical os. Conclusions: During CCBD, the internal cervical os is the centre of cervical resistance, and the values do not decline with the number of miscarriages or the number of previous births. Trial registration number: ISRCTN Registry identifier: ISRCTN30949871. Date of registration: 13 May 2015 [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Electromagnetic field investigation on different cancer cell lines.
- Author
-
Filipovic, Nenad, Djukic, Tijana, Radovic, Milos, Cvetkovic, Danijela, Curcic, Milena, Markovic, Snezana, Peulic, Aleksandar, and Jeremic, Branislav
- Subjects
CANCER cells ,ELECTROMAGNETIC devices ,CARCINOGENS ,CELL lines ,CELL culture - Abstract
Background There is a strong interest in the investigation of extremely low frequency Electromagnetic Fields (EMF) in the clinic. While evidence about anticancer effects exists, the mechanism explaining this effect is still unknown. Methods We investigated in vitro, and with computer simulation, the influence of a 50 Hz EMF on three cancer cell lines: breast cancer MDA-MB-231, and colon cancer SW-480 and HCT- 116. After 24 h preincubation, cells were exposed to 50 Hz extremely low frequency (ELF) radiofrequency EMF using in vitro exposure systems for 24 and 72 h. A computer reactiondiffusion model with the net rate of cell proliferation and effect of EMF in time was developed. The fitting procedure for estimation of the computer model parameters was implemented. Results Experimental results clearly showed disintegration of cells treated with a 50 Hz EMF, compared to untreated control cells. A large percentage of treated cells resulted in increased early apoptosis after 24 h and 72 h, compared to the controls. Computer model have shown good comparison with experimental data. Conclusion Using EMF at specific frequencies may represent a new approach in controlling the growth of cancer cells, while computer modelling could be used to predict such effects and make optimisation for complex experimental design. Further studies are required before testing this approach in humans. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Computer simulation of cervical tissue response to a hydraulic dilator device.
- Author
-
Filipovic, Nenad, Nikolic, Dalibor, Saveljic, Igor, Tanaskovic, Irena, Zdravkovic, Nebojsa, Zivanovic, Aleksandar, Arsenijevic, Petar, Jeremic, Branislav, and Arsenijevic, Slobodan
- Abstract
Background: Classical mechanical dilators for cervical dilation are associated with various complications, such as uterine perforation, cervical laceration, infections and intraperitoneal hemorrhage. A new medical device called continuous controllable balloon dilator (CCBD) was constructed to make a significant reduction in all of the side effects of traditional mechanical dilation. Method: In this study we investigated numerically the cervical canal tissue response for Hegar and CCBD using our poroelastic finite element model and in-house software development. Boundary conditions for pressure loading on the tissue for both dilators in vivo were measured experimentally. Material properties of the cervical tissue were fitted with experimental in vivo data of pressure and fluid volume or balloon size. Results: Obtained results for effective stresses inside the cervical tissue clearly showed higher stresses for Hegar dilator during dilation in comparison with our CCBD. Conclusion: This study opens a new avenue for the implementation of CCBD device instead of mechanical dilators to prevent cervical injury during cervical dilation. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
10. Continuous controllable balloon dilation: a novel approach for cervix dilation.
- Author
-
Arsenijevic, Slobodan, Vukcevic-Globarevic, Gordana, Volarevic, Vladislav, Macuzic, Ivan, Todorovic, Petar, Tanaskovic, Irena, Mijailovic, Milan, Raicevic, Sasa, and Jeremic, Branislav
- Subjects
PREGNANT women ,MUCOUS membranes ,UTERINE perforation ,MEDICAL care ,CLINICAL medicine - Abstract
Background: Cervical dilation using mechanical dilators is associated with various complications, such as uterine perforation, cervical laceration, infections and intraperitoneal hemorrhage. To achieve safe and painless cervical dilation, we constructed a new medical device to achieve confident mechanical cervical dilation: a continuous controllable balloon dilator (CCBD). Methods: Controlled pumping of incompressible fluid into the CCBD increases the pressure and outer diameter of the CCBD, continuously dilating the cervical canal. The reliability of the CCBD was confirmed in vitro (testing for consistency and endurance, with no detected risk for breakage) and in vivo. A multi-center clinical study was conducted,with 120 pregnant women randomly assigned to one of three groups: Group I,control group, no dilation;Group II,mechanical dilation, Hegar dilator (HeD); and Group III,CCBD. The tissue material for histological evaluation was obtained from the endocervical mucosa before and after dilation using the HeD or CCBD. Results: The CCBD dilations were successful and had no complications in all 40 patients of Group III. The cervical tissue was markedly less damaged after CCBD dilation compared with HeD dilation (epithelium damage: 95% (HeD) vs. 45% (CCBD), P <0.001; basal membrane damage: 82.5% (HeD) vs. 27.5% (CCBD), P <0.001; stromal damage: 62.5% (HeD) vs. 37.5% (CCBD), P <0.01). Cervical hemorrhagia was observed in 90% of the patients after HeD dilation versus in 32.5% of the patients after CCBD dilation. Conclusions: The CCBD should be used as a replacement for mechanical dilators to prevent uterine and cervical injury during cervical dilation. Trial registration: ISRCTN54007498 [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
11. Current status and perspectives of interventional clinical trials for glioblastoma - analysis of ClinicalTrials.gov
- Author
-
Cihoric, Nikola, Tsikkinis, Alexandros, Minniti, Giuseppe, Lagerwaard, Frank J, Herrlinger, Ulrich, Mathier, Etienne, Soldatovic, Ivan, Jeremic, Branislav, Ghadjar, Pirus, Eliçin, Olgun, Lössl, Kristina, Aebersold, Daniel, Belka, Claus, Herrmann, Evelyn, and Niyazi, Maximilian
- Subjects
610 Medicine & health ,3. Good health - Abstract
The records of 208.777 (100%) clinical trials registered at ClinicalTrials.gov were downloaded on the 19th of February 2016. Phase II and III trials including patients with glioblastoma were selected for further classification and analysis. Based on the disease settings, trials were classified into three groups: newly diagnosed glioblastoma, recurrent disease and trials with no differentiation according to disease setting. Furthermore, we categorized trials according to the experimental interventions, the primary sponsor, the source of financial support and trial design elements. Trends were evaluated using the autoregressive integrated moving average model. Two hundred sixteen (0.1%) trials were selected for further analysis. Academic centers (investigator initiated trials) were recorded as primary sponsors in 56.9% of trials, followed by industry 25.9%. Industry was the leading source of monetary support for the selected trials in 44.4%, followed by 25% of trials with primarily academic financial support. The number of newly initiated trials between 2005 and 2015 shows a positive trend, mainly through an increase in phase II trials, whereas phase III trials show a negative trend. The vast majority of trials evaluate forms of different systemic treatments (91.2%). In total, one hundred different molecular entities or biologicals were identified. Of those, 60% were involving drugs specifically designed for central nervous system malignancies. Trials that specifically address radiotherapy, surgery, imaging and other therapeutic or diagnostic methods appear to be rare. Current research in glioblastoma is mainly driven or sponsored by industry, academic medical oncologists and neuro-oncologists, with the majority of trials evaluating forms of systemic therapies. Few trials reach phase III. Imaging, radiation therapy and surgical procedures are underrepresented in current trials portfolios. Optimization in research portfolio for glioblastoma is needed.
12. Portfolio of prospective clinical trials including brachytherapy: an analysis of the ClinicalTrials.gov database
- Author
-
Tsikkinis, Alexandros, Jeremic, Branislav, Strnad, Vratislav, Dal Pra, Alan, Aebersold, Daniel, Soldatovic, Ivan, Miguelez, Cristina Gutierrez, Ghadjar, Pirus, Lössl, Kristina, and Cihoric, Nikola
- Subjects
610 Medicine & health ,3. Good health - Abstract
BACKGROUND To evaluate the current status of prospective interventional clinical trials that includes brachytherapy (BT) procedures. METHODS The records of 175,538 (100 %) clinical trials registered at ClinicalTrials.gov were downloaded on September 2014 and a database was established. Trials using BT as an intervention were identified for further analyses. The selected trials were manually categorized according to indication(s), BT source, applied dose rate, primary sponsor type, location, protocol initiator and funding source. We analyzed trials across 8 available trial protocol elements registered within the database. RESULTS In total 245 clinical trials were identified, 147 with BT as primary investigated treatment modality and 98 that included BT as an optional treatment component or as part of the standard treatment. Academic centers were the most frequent protocol initiators in trials where BT was the primary investigational treatment modality (p < 0.01). High dose rate (HDR) BT was the most frequently investigated type of BT dose rate (46.3 %) followed by low dose rate (LDR) (42.0 %). Prostate was the most frequently investigated tumor entity in trials with BT as the primary treatment modality (40.1 %) followed by breast cancer (17.0 %). BT was rarely the primary investigated treatment modality for cervical cancer (6.8 %). CONCLUSION Most clinical trials using BT are predominantly in early phases, investigator-initiated and with low accrual numbers. Current investigational activities that include BT mainly focus on prostate and breast cancers. Important questions concerning the optimal usage of BT will not be answered in the near future.
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.